This is an international site for Glivec^® (imatinib) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Welcome to the GLIVEC Product Website

GLIVEC is approved for use in 116 countries around the world.

GLIVEC Country-Level Websites

Below is a list of the countries that host a GLIVEC website based on local label and in local language. They are intended for Health Care Professionals (HCPs) only. If you are a HCP from one of the countries listed below, click on your country link to be redirected to your country Glivec website.

GLIVEC International Website

This website is intended for Health Care Professionals (HCPs) outside the U.S. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information via www.novartisoncology.com/contactus.

IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EUSmPC)

Extending Adjuvant GLIVEC Patient Image/Global

NEW TRIAL DATA

With 3 years of adjuvant therapy in KIT+ GIST patients, at 5-year analysis, GLIVEC provided¹

92% OVERALL SURVIVAL
66% RECURRENCE-FREE SURVIVAL

LEARN MORE

Gastrointestinal Stromal
Tumor (GIST)
Risk of Recurrence Calculator

Download this convenient interactive tool to quickly assess your patients risk of KIT+GIST recurrence, based on tumor size, tumor site, and mitotic rate.

DOWNLOAD

GIST Recurrence Post Adjuvant Therapy Patient Image/Global

In advance disease,
GLIVEC EXTENDED OVERALL SURVIVAL TO

57 MONTHS
FROM 10 MONTHS^2,3